Unraveling the Heart-Health Puzzle in Prostate Cancer Therapy: A New Trial's Approach
The Battle Against Cancer's Unintended Effects: A Critical Mission
City of Hope, a leading cancer research and treatment powerhouse in the U.S., is embarking on a phase 2 clinical trial to tackle a pressing issue: protecting heart health in prostate cancer patients undergoing androgen deprivation therapy (ADT). This therapy, while life-saving, can have unintended consequences on cardiometabolic health, and City of Hope aims to mitigate these risks.
Dr. YunRose Li, a principal investigator and assistant professor at City of Hope's Department of Radiation Oncology, emphasizes the importance of addressing these metabolic and cardiovascular side effects to enhance overall patient outcomes and reduce long-term complications.
The Study's Focus: Unlocking the Best Strategies for Heart Health
The trial aims to compare three distinct strategies to offset the risks associated with ADT, allowing patients to continue their cancer treatment without compromising their heart health. Prostate cancer patients on ADT face an increased risk of cardiovascular diseases, including heart attacks, strokes, and other vascular issues. These risks are often linked to treatment-induced metabolic changes, leading to weight gain, insulin resistance, and increased body fat.
Dr. Li's lab has been dedicated to mitigating the side effects of cancer treatments, including radiotherapy and ADT, and this new trial builds upon her previous work in this field.
Three Approaches Under the Microscope
The trial will evaluate three approaches:
- Intermittent Fasting: Participants will fast for 16 hours, a strategy known to have metabolic benefits.
- Anti-Obesity Medication: This medication targets the body's natural glucagon-like peptide-1 (GLP-1) signaling pathway, which plays a crucial role in diabetes management.
- American Heart Association's Life's Essential 8 Guidelines: A comprehensive set of guidelines for heart health.
Participants will follow one of these approaches for six months while continuing their cancer treatment, which includes radiation and hormone therapy.
Assessing the Impact: A Comprehensive Evaluation
Researchers will conduct thorough assessments of participants' metabolic and cardiovascular health, utilizing clinical endpoints, biomarkers, imaging, and other tools. Patients will be closely monitored for 12 months post-intervention to evaluate the long-term effects.
The Trial's Primary Objective: Feasibility and Safety
The primary goal of the trial is to determine the feasibility and safety of these interventions for prostate cancer patients on hormone therapy. These strategies, while widely used in other clinical settings, need to be evaluated specifically for this patient population.
Dr. June-Wha Rhee, an associate professor in City of Hope's Division of Cardiology and a fellow study investigator, highlights the importance of identifying the most beneficial strategy for cardiometabolic health and understanding which patients will gain the most from prophylactic interventions. This knowledge will shape future cancer care practices and guide further research in mitigating treatment-related metabolic and cardiovascular risks.
A Call for Discussion: Where Do You Stand?
This trial raises intriguing questions: Which strategy do you think will prove most effective in protecting heart health during prostate cancer therapy? And how can we ensure that patients receive the best possible care while managing the unintended effects of life-saving treatments? Share your thoughts and insights in the comments below!
